

1 **Live virus neutralizing antibodies against pre and post Omicron strains in food and retail**
2 **workers in Québec, Canada.**

3
4 Henintsoa Rabezanaahary^{1,2}, Caroline Gilbert^{1,2}, Kim Santerre^{1,2}, Martina Scarrone^{1,2}, Megan
5 Gilbert^{1,2}, Mathieu Thériault^{1,2}, Nicholas Brousseau^{1,3}, Jean-François Masson⁴, Joelle N. Pelletier⁵,
6 Denis Boudreau⁶, Sylvie Trottier^{1,2} and Mariana Baz^{1,2*}

7
8 ¹Division of Infectious and Immune Diseases, CHU de Québec Research Center, QC, Quebec,
9 Canada.

10
11 ²Department of Microbiology, Infectious Disease and Immunology, Faculty of Medicine,
12 Université Laval, QC, Quebec, Canada.

13
14 ³Biological Risks Department, Institut national de santé publique du Québec, Québec, QC G1V
15 5B3, Canada

16
17 ⁴Department of Chemistry, Quebec Center for Advanced Materials, Regroupement québécois sur
18 les matériaux de pointe, and Centre interdisciplinaire de recherche sur le cerveau et l'apprentissage,
19 Université de Montréal, Montréal, Canada.

20
21 ⁵Department of Chemistry, Department of Biochemistry, Université de Montréal, Montréal, QC
22 H2V 0B3, Canada and PROTEO-The Québec Network for Research on Protein Function,
Engineering, and Applications, Québec, Canada.

23
24 ⁶Département de chimie et Centre d'optique, photonique et laser (COPL), Université Laval,
Québec, Canada.

25 **Running title:** SARS-CoV-2 NtAbs in food/retail workers.

26 Abstract count: 199

27 Main text count: 3535

28 Inserts: 3 figures, 2 tables, 3 supplementary figures,

29 References: 40

30
31
32 *Corresponding author:

33
34
35 **Mariana Baz, PhD**

36 Infectious Disease Research Centre

37 CHU de Quebec and Laval University

38 Québec, Canada G1V 4G2

39 Tel.: (418) 525-4444 ext. 48281

40 Fax: (418) 654-2715

41 Email: mariana.baz@crchudequebec.ulaval.ca

42

43

1 **Abstract**

2
3

4 **Objectives.** To assess the neutralization activity pre and post Omicron BA.1 emergence in a
5 unique cohort of 280 vaccinated restaurant/bar, grocery and hardware store workers in Québec,
6 Canada.

7

8 **Methods.** Participants were recruited during the emergence of Omicron BA.1 variant. The
9 neutralizing activity of participant sera was assessed by microneutralization assay.

10

11 **Results.** Serum neutralizing antibody (NtAb) titers of all participants against the ancestral SARS-
12 CoV-2 strain was comparable with the response against Delta variant, however, their response was
13 significantly reduced against Omicron BA.1, BA2, BA.2.12.1, BA.4 and BA.5. The neutralizing
14 response of each group of workers was similar. Individuals who received 2 doses of vaccine had
15 significantly reduced NtAb titers against all SARS-CoV-2 strains compared to those infected and
16 then vaccinated (≥ 1 dose), vaccinated (≥ 2 doses) and then infected, or those who received 3 doses
17 of vaccine. Participants vaccinated with 2 or 3 doses of vaccine and then infected had the highest
18 NtAb titers against all SARS-CoV-2 strains tested.

19

20 **Conclusion.** We assessed for the first time the NtAb response in food and retail workers.
21 Individuals infected after ≥ 2 doses of vaccine had the highest levels of NtAbs against Omicron
22 BA.1, BA.2 and BA.5 variants and might be better protected against reinfection.

23

24 **Keywords:** neutralizing antibodies, food/retail workers, SARS-CoV-2 variants, vaccines.

25
26

1 **Introduction**

2
3 Since the beginning of the Coronavirus Disease 2019 (COVID-19) pandemic, the global response
4 has faced new challenges including the emergence of new severe acute respiratory syndrome
5 coronavirus 2 (SARS-CoV-2) variants of concern (VOC). In late 2020, the B.1.617.2 (Delta)
6 variant was identified in India [1] and spread widely throughout the world. This variant harbors
7 nine mutations in the viral spike (S) protein which alter biological characteristics such as binding
8 affinity between the receptor binding domain (RBD) and the angiotensin-converting enzyme-2
9 (ACE2) receptor [2], as well as transmissibility and immune evasion [3]. In November 2021,
10 Omicron (BA.1 sub-lineage of the B.1.1.529) variant emerged in South Africa [4] and rapidly
11 spread around the world, becoming the dominant SARS-CoV-2 variant. Omicron BA.1 has
12 acquired a large number of substitutions (>30), deletions and insertions in the spike protein and
13 has been shown to escape protection conferred by vaccines and therapeutic monoclonal
14 antibodies[5]. Since January 2022, several other Omicron sub-lineages have been detected such as
15 BA.2, BA.2.12.1 (a variant of BA.2), BA.2.75, BQ.1.1, BA.4/5 and more recently XBB.1.5,
16 XBB.1.16 and EG.5 [6]. Therefore, the global dynamic landscape of SARS-CoV-2 sub-genomes
17 has become increasingly complex causing waves of infection in people with variable immunity
18 induced by both infection and/or vaccination and have shown greatest evasion against parental or
19 bivalent BA.1 or BA.4/5 mRNA-booster vaccines, explaining the rapid spreading of these new
20 sub-lineages [7].

21
22 Neutralizing antibodies are crucial for virus clearance and are a major determinant of protection
23 from infection in humans [8] and macaques challenged with SARS-CoV-2 [9]. In contrast with
24 influenza infections, where a hemagglutination inhibition titer of 1:40 is thought to provide 50%

1 protection from influenza infection [10], in the case of COVID-19, the role of NtAbs with regard
2 to disease outcome remains undefined. It is also possible that neutralization is correlated with other
3 immune responses such as T cell responses and B cell memory responses, which have also shown
4 to contribute to protection [11]. Modeling studies have been used to estimate protective
5 neutralization titer for COVID-19 [11], however, further studies and validations are needed.

6 Serological studies of SARS-CoV-2 antibodies have been conducted in several countries but have
7 been focused on hospital and primary healthcare workers, blood donors, school children and staff
8 and nursing homes [12-16]. Retail workers such as those working in grocery and hardware stores,
9 restaurants and bars have been poorly or not studied.

10 In this study, we compared the neutralizing antibody levels in serum samples (n=280) against the
11 ancestral SARS-CoV-2, Delta, Omicron BA.1, BA.2, BA.2.12.1, BA.4 and BA.5 strains, from a
12 unique population composed by four groups of non-hospitalized (vaccinated, vaccinated and
13 infected or vice versa) retail workers, including grocery and hardware stores, restaurants and bar
14 workers in Quebec, Canada.

15 **METHODS**

16 **Study participants**

17 The 280 vaccinated participants were derived from a study which consisted of 304 food and retail
18 workers who were recruited as part of a longitudinal study to assess the humoral and cellular
19 responses to SARS-CoV-2 and its VOC in four groups of non-hospitalized retail workers [17].
20 Individuals were recruited in the Québec City area, specifically in the administrative regions of
21 Capitale-Nationale and Chaudière-Appalaches, in Québec, Canada. The recruitment took place

1 from October 2021 to May 2022, during the emergence of Omicron BA.1 variant, and individuals
2 were classified into two groups: aged 18 to 59 and ≥ 60 years old. All participants provided
3 information about vaccination and/or infection. The study was reviewed and approved by the CHU
4 de Quebec-Université Laval Research Ethics Board (registration number 2021-5744). All
5 experiments were performed in accordance with relevant guidelines and regulations. Adult
6 volunteers were recruited at the *Centre Hospitalier Universitaire de Québec-Université Laval*
7 (CHUL) in Quebec City. All participants provided informed written consent before enrolling. The
8 study data is shared through the Maelstrom platform on a periodic basis as each visit is completed
9 (<https://www.maelstrom-research.org/study/cisacov>).

10 **Sample Collection and Processing**

11 Blood was collected in 6 mL tubes for serum, gently inverted, held at room temperature for 15-30
12 minutes and centrifuged at 1600 x g for 15 minutes. Aliquots of 1 mL of serum were transferred
13 in cryovials and frozen at -20°C until used.

14 **Cells and viruses**

15 Virus stocks used in this study were propagated in African green monkey kidney E6 cell line (Vero
16 American Type Culture Collection, ATCC® CRL-1586TM) or Calu-3 cells (ATCC-HTB-55) in
17 2% of Fetal Bovine Serum MEM and stored at -80°C until use. Live microneutralization assays
18 were done in Vero E6 (ancestral SARS-CoV-2 and Delta variant) or Vero cells overexpressing
19 transmembrane protease serine 2 (TMPRSS2, JCRB), (Omicron BA.1, BA.2, BA.2.12.1, BA.4
20 and BA.5 variants) cell lines. SARS-CoV-2/Québec City/21697/2020 strain (ancestral Wuhan-1
21 like SARS-CoV-2), was isolated from a clinical sample in March 2020 in Quebec City, Canada.

1 Delta (SARS-CoV-2 VOC B.1.617.2) and Omicron sub-lineages BA.1 (SARS-CoV-2 VOC
2 B.1.1.529) and BA.2, BA.2.12.1, BA.4 and BA.5 were obtained from the National Microbiology
3 Laboratory (NML), Public Health Agency of Canada.

4 **Live microneutralization assay**

5 Microneutralization assays, the gold standard for evaluating virus NtAbs, were performed as
6 previously described for influenza virus [18, 19] with some modifications. Briefly, sera from the
7 participants were heat-inactivated (30 minutes at 56 °C), and serial two-fold dilutions were
8 prepared from a 1:20 to 1:10,240 dilution of each sample. Equal volumes of serum and virus (100
9 TCID₅₀ (50% tissue culture infectious dose) of each SARS-CoV-2 strain) were mixed and
10 incubated for 60 min at room temperature. The residual infectivity of the virus-serum mixture was
11 determined in Vero (ancestral and Delta variant) or Vero TMPRSS2, (Omicron BA.1 and BA.2,
12 BA.2.12.1, BA.4 and BA.5 variants) cell lines using four wells for each dilution of serum. A virus
13 back titration, positive controls (high, medium, and low titers) and negative controls were included
14 in every experiment. Neutralizing antibody titer was defined as the reciprocal of the serum dilution
15 that completely neutralized the infectivity of 100 TCID₅₀ of each SARS-CoV-2 strain as
16 determined by the absence of cytopathic effect on Vero or Vero TMPRSS2 cells at day 4 as
17 previously described [18-20]. The neutralizing antibody titers are presented as geometric mean
18 titre (GMT). These studies were performed in the Containment Level 3 (CL3) laboratory at the
19 *CHU de Québec-Université Laval*.

20 **Statistical analysis**

21 Sera with undetectable (<20) antibody titers were assigned an antibody titer of 10 for purposes of
22 GMT calculations or statistical comparisons. Comparison between antibody titers against ancestral

1 SARS-CoV-2, Delta and Omicron BA.1, BA2, BA.2.12.1, BA.4 and BA.5 variants were
2 performed with Kruskal-Wallis one-way ANOVA followed by Dunn's multiple comparison test,
3 using GraphPad Prism 9.0 (GraphPad Software, Inc, San Diego, CA).

4 **RESULTS**

5 We included 280 vaccinated participants; 105 (37%), 133 (48%) and 42 (15%) worked in grocery
6 stores, restaurants/bars or in hardware stores, respectively (Table 1). The median age of the 280
7 vaccinated participants was 41 years old (range 18-74) and 158 (56%) were females. Median body
8 mass index was 26 kg/m² (range 17-50). Chronic diseases (e.g., hypertension, diabetes, asthma,
9 chronic lung, heart, kidney or liver disease, cancer, chronic blood disorder, immunosuppression,
10 chronic neurological disorder), were present in 117 (42%) of the participants. Fifty-nine (21%) of
11 the participants were smokers or e-cigarette users (vaping) (Table 1).

12 Participants had been vaccinated with ≥ 1 dose of vaccine (messenger RNA (mRNA) vaccine
13 BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna) or with viral vector vaccine ChAdOx1-S
14 (AstraZeneca)), (Table 2). We analyzed participants regarding the number of vaccine doses
15 received and if they were infected before or after vaccination and separated them in four groups:
16 1) infected and then vaccinated with 1-3 doses (n=16), 2) vaccinated with 2 doses (n=144), 3)
17 vaccinated with 3 doses (n=84), and 4) vaccinated with 2-3 doses and then infected (n=36). We
18 have considered participants in each group taking into consideration ≥ 7 days between last
19 vaccination (or infection) and sample collection. The median delay between the last dose of
20 vaccine or infection and the blood sample collection for group 1 was 315, 168 and 13 days for
21 those who received one (n=2), two (n=11) or three doses of vaccine (n=3), respectively; for group
22 2 it was 157 days (n=144); for group 3 it was 48 days (n=84) and for group 4 it was 44 and 23 days

1 for those who received two doses (n=28) and three doses of vaccine (n=8), respectively, (Table 2).
2 The neutralizing antibody titers after the most recent vaccine dose or infection and the sample
3 collection for each group stratified in intervals between 7-30 days, 31-60 days, 61-90 days and
4 over 90 days is presented in Supplementary Figure 1.

5 By the time of Omicron BA.1 emergence, 82% (86/105), 77% (103/133) and 81% (34/42) of
6 grocery workers, restaurant/bar workers and hardware workers, respectively, were seropositive for
7 ancestral SARS-CoV-2 and 80% (84/105), 77% (103/133) and 79% (33/42) were seropositive for
8 the Delta variant. However, only 46% (48/105), 44% (59/103) and 38% (16/42) had cross-NtAbs
9 against BA.1 variant.

10 Serum neutralizing antibody titers of all participants (n=280) against the ancestral SARS-CoV-2
11 strain was comparable with the response against Delta variant, with a geometric mean titer (GMT)
12 of 76 (range 10-2032) and 71 (10-2560), respectively (Figure 1A). However, live NtAb response
13 was reduced against the other variants tested, where the GMTs against BA.1, BA2, BA.2.12.1,
14 BA.4 and BA.5 were 23 (range 10-1016), 26 (10-1016), 19 (10-320), 12 (10-80) and 17 (10-254),
15 respectively. Thus, compared with the GMT of the ancestral SARS-CoV-2 strain, the neutralizing
16 GMTs of the BA.1, BA2, BA.2.12.1, BA.4 and BA.5 were reduced by 3.3-, 3.0-, 4.0-, 6.3-, and
17 4.7-fold, respectively, ($p<0.0001$, Figure 1A). GMTs of BA.1 were 1.2-, 1.9-, and 1.4-fold higher
18 compared to BA.2.12.1, BA.4 and BA.5, respectively, ($p<0.0001$, Figure 1A). No statistical
19 difference was observed in the GMTs of each group of workers against each of the SARS-CoV-2
20 strain tested (Figure 1B). When we compared the GMTs against all SARS-CoV-2 strains of each
21 of the groups (grocery and hardware stores and restaurant/bars), we observed a similar pattern than
22 the whole cohort (Supplementary Figure 2).

1 We examined additional factors that may contribute to the NtAb response to vaccination or
2 vaccination/infection (or vice-versa) in our food and retail workers cohort (all groups together)
3 including sex and age, against all SARS-CoV-2 strains. We found a similar pattern in the humoral
4 response in males (n=122) and females (n=158) between ancestral SARS-CoV-2 and the other
5 variants. The GMTs against ancestral, Delta, BA.1, BA2, BA.2.12.1, BA.4 and BA.5 strains were
6 80, 69, 22, 24, 18, 12 and 16, respectively, for males (Figure 2A) and 74, 72, 23, 26, 19, 12, and
7 17, respectively, for females (Figure 2B). We did not find any significant difference between the
8 age groups of <60 years (n=236, median 37 (range 18-59)) and ≥ 60 years (n=44, median 64 (range
9 60-73)) when we compared the GMT for the ancestral SARS-CoV-2 and Delta variants (GMT of
10 76 and 72 (10-1280) for both strains (p=0.99)). A 3.3-, 2.9-, 4.0-, 6.3- and 4.7-fold reduction was
11 observed for BA.1, BA2, BA.2.12.1, BA.4 and BA.5 strains, respectively, when compared to the
12 ancestral SARS-CoV-2, (Figure 2C) among participants of <60 years of age and a 3.8-, 3.3-, 4.4-,
13 6.7- and 4.7-fold reduction was observed against the same strains among participants of ≥ 60 years
14 old (Figure 2D). No statistically significant differences were found in the GMTs against any
15 SARS-CoV-2 strain in relation to the presence of chronic diseases and to smoking or vaping
16 (Supplementary Figure 3). Interestingly, we found significantly higher GMTs against all strains
17 except Delta in females with BMI ≥ 30 (Supplementary Figure 3C) as well as in smokers or vaping
18 males, although in the latter group was only against Omicron BA.2.12.1 strain.

19 The GMTs against the ancestral SARS-CoV-2 strain were statistically lower for group 2 (2 doses
20 of vaccine, GMT=30) than for other groups: group 1 (infected, vaccinated with ≥ 1 dose,
21 GMT=160, $p=0.0021$), group 3 (vaccinated with 3 doses, GMT=204, $p<0.0001$), group 4
22 (vaccinated with ≥ 2 dose and infected, GMT=221, $p<0.0001$) (Figure 3A). A similar profile was
23 seen among the 4 groups against Delta variant. GMTs were lower in all groups against the other

1 SARS-CoV-2 Omicron variants (BA.1, BA.2, BA.2.12.1, BA.4 and BA.5). Of note, the GMT of
2 participants who were vaccinated with 2 or 3 doses of vaccine and then infected (group 4) had
3 consistently higher NtAb titers against all variant tested, although a statistical significance was not
4 always observed (Figure 3A). A similar trend was found for the other SARS-CoV-2 variants.
5 Figure 3B shows the NtAb titers against each of the SARS-CoV-2 strains tested for participants of
6 the 4 groups, each subgroup representing the type of vaccine regimen they have received. No
7 significant differences were observed in the GMTs of the different subgroups against the ancestral
8 SARS-CoV-2, except for those individuals who were vaccinated with 2 doses of Moderna
9 (GMT=43) versus those who received AstraZeneca/Pfizer or AstraZeneca/Moderna (GMT=15),
10 where a 2.9-fold reduction was observed ($p = 0.01$). Regarding the Delta variant, the combination
11 of 2 doses of Pfizer ($p = 0.03$) or Moderna ($p = 0.0026$) or 3 doses of Pfizer ($p = 0.0157$) showed
12 better response than a mixed schedule containing the AstraZeneca vaccine. Similar patterns were
13 seen against BA.1 and BA.2 variants, but no significant differences were found when analyzing
14 against BA.2.12.1, BA.4 and BA.5 (Figure 3B).

15 16 **DISCUSSION**

17
18 One of the important roles of vaccination is to generate broad, long-lasting immunity that will
19 contribute to protect individuals from future infections or at least from severe clinical outcomes if
20 infected. Since the emergence of the Omicron lineage in late 2021, several Omicron variants
21 continue to evolve into new subvariants which are increasingly resistant to monovalent and
22 bivalent vaccination [21-24].

23

1 During the first two years of the COVID-19 pandemic (i.e from March 2020 to February 2022),
2 the provincial government of Québec in Canada has used a plethora of measures and restrictions
3 on its territory in an attempt to reduce the infection rate. These measures included house
4 confinement, curfew, suspension of activities deemed non-essential, including within the
5 manufacturing and service industry, and mandatory online class for school and university (no face-
6 to-face). These measures varied in time and length and were generally implemented based on
7 infection rate within sub-regions of the province. During this period, grocery stores were
8 considered essential institutions in support of food and general supplies, and remained open most
9 of the time. Public health measures (e.g., mask wearing, social distancing, staying home when
10 sick, etc.) were enforced and generally well-respected. Hardware stores and restaurants were
11 instead intermittently opened and closed by health authorities over the same period, and were at
12 higher risk of SARS-CoV-2 transmission due to the intrinsically social nature of these businesses
13 and difficulty to enforce public health measures. In December 2020, vaccines were approved in
14 Canada and priority was given to essential workers as a measure to protect themselves, their
15 families, co-workers, and their community, while ensuring the constant availability of
16 food/hardware supplies.

17
18 Many studies have been performed to analyze the antibody response of health-care workers, school
19 children and staff and nursing homes in Canada and elsewhere [12-14, 21, 23-25], however, no
20 serological studies in a cohort of food/retail workers have been conducted in Canada.

21
22 Antibody measurements are a crucial aspect of estimating the level of herd immunity in
23 communities. Importantly, NtAbs are important for virus clearance and their titers have been

1 demonstrated to be correlated with vaccine efficacy [11, 26, 27]. Indeed, several studies have
2 shown that high levels of NtAbs are associated with protection from symptomatic SARS-CoV-2
3 infection after vaccination [11, 28, 29], however, all the studies have different approaches to
4 estimate the relationship between NtAb titers and vaccine efficacy. A recent study performed by
5 Khoury et al. [26] has analyzed four phase 3 clinical studies evaluating the performance of
6 COVID-19 vaccines against the ancestral SARS-CoV-2 strain at the beginning of the vaccine
7 campaign and before the emergence of the VOCs. Each study [11, 28-30] reported on a significant
8 relationship between neutralizing titers and vaccine efficacy using different neutralization
9 methodologies. Interestingly, Khoury et al. found that when centering the data on the GMT elicited
10 by the vaccine, the four studies converged on a common correlating prediction between
11 neutralization capacity and protection against infection [26], supporting the use of NtAb titers to
12 predict the efficacy of new vaccines or vaccine efficacy against new VOCs (when fold drop in
13 NtAb titer for the variant can be estimated).

14
15 In this study we compared the neutralizing antibody levels against the ancestral SARS-CoV-2,
16 Delta, Omicron BA.1, BA.2, BA.2.12.1, BA.4 and BA.5 strains in 280 serum samples collected
17 from vaccinated food and retail workers including those from grocery and hardware stores,
18 restaurants and bars recruited in the Québec City area (Capitale-Nationale and Chaudière-
19 Appalaches administrative regions) during the emergence of Omicron BA.1 variant (October 2021
20 to May 2022). By the time of the sample collection, all participants had received at minimum one
21 dose of either mRNA vaccines (BNT162b2, Pfizer-BioNTech); mRNA-1273, Moderna) or viral
22 vector vaccine (ChAdOx1-S, AstraZeneca).

23

1 When we analyzed each of the participating groups of workers (grocery stores, restaurants/bars or
2 hardware stores), no statistical difference was observed in the GMTs of the groups against any of
3 the SARS-CoV-2 strains tested. Overall, when considering all participants, we found no statistical
4 difference in the NtAb titers against the ancestral SARS-CoV-2 strain and the Delta variant. In
5 general, the NtAb response was reduced against the other variants tested, where the GMTs against
6 BA.1, BA.2, BA.2.12.1, BA.4 and BA.5 were reduced by 3.3-, 3-, 4-, 6.3-, and 4.7-fold compared
7 to the ancestral SARS-CoV-2, respectively. This decreasing pattern of NtAb response is in line
8 with studies reported in other populations such as healthcare workers, healthy vaccinated adults
9 and adolescents and immunocompromised patients [31-37]. No statistically significant difference
10 in the GMTs was observed between male/female participants, age groups (<60 years versus ≥60
11 years) and in males and females with chronic disease, smoking or vaping or among those
12 volunteers with all three characteristics. Interestingly, our study found a significant difference in
13 the GMTs against all SARS-CoV-2 strains tested except Delta in obese females (BMI ≥30; n=48;
14 median delay of 95 days between last vaccination/infection and samples collection for BMI≥30
15 versus 96 days for BMI<30). Of note, according to the vaccine safety and efficacy information for
16 Pfizer, Moderna, and Johnson & Johnson formulations showed similar efficacy in individuals with
17 or without obesity [38]. However, a systematic review [39] of published studies on the safety and
18 efficacy of COVID-19 vaccine in people who were overweight or obese reported that in nine out
19 of twelve studies a reduced response with increased BMI was observed. Importantly, contradictory
20 results may be due to different measure of obesity (e.g. central obesity or BMI), vaccination,
21 comorbidities, the use of antibody titer kits or assays, age, sex, measuring antibodies at varying
22 time points, etc. Therefore, more research needs to be done to assess the impact of obesity on
23 immunogenicity of SARS-CoV-2 vaccines.

1 The seroprevalence of ancestral SARS-CoV-2 antibodies in the 280 participants during the period
2 of October 2021 to May 2022 (emergence of the first Omicron sub-lineage (BA.1) was 80%.
3 Cross-variant neutralization capacity was found in 99%, 55%, 58%, 46%, 21% and 39% of the
4 participants against the Delta, BA.1, BA.2, BA.2.12.1, BA.4 and BA.5, respectively. Similar to
5 other studies in different groups of individuals [21, 31-37, 40], our data show that uninfected food
6 and retail workers from Québec who received 2 doses of vaccine had significantly lower NtAb
7 titers against the ancestral SARS-CoV-2 and all variants than those who were infected and then
8 vaccinated (≥ 1 dose), vaccinated (≥ 2 doses) and then infected, or those who received 3 doses of
9 vaccine. As previously reported, hybrid immunity led to better humoral response against SARS-
10 CoV-2 variants than vaccination alone, as participants who were infected after two or three doses
11 of vaccine had higher NtAbs levels against BA.1, BA.2 and BA.5 variants, compared with other
12 groups, suggesting a substantial degree of cross-reactive natural immunity. Therefore, workers
13 with hybrid immunity acquired during Omicron BA.1 emergence might be better protected against
14 reinfection with subsequent Omicron variants such as BA.2, BA.4/5 etc.

15
16 Our study has several limitations. An important limitation is that the interval between the last
17 vaccination/infection and sample collection was variable; for example, for participants who
18 received 2 or 3 doses of vaccine, the delay was 157 and 48 days (median), respectively, amplifying
19 the potential difference in the antibody response. Importantly, our conclusions concerning the
20 differences between the 4 groups apply even when comparing GMTs for similar intervals. We
21 were also unable to confirm the specific SARS-CoV-2 strain that caused the infection among
22 participants. The use of different vaccine platforms finally highlights a potential limitation of our

1 study as the immunogenicity of each vaccine type differs. Reassuringly, however, almost all
2 participants (279/280) received at least one mRNA vaccine.

3
4 In summary, we assessed for the first time the neutralizing antibody response of a unique
5 population of food and retail workers. Overall, we found that vaccination was associated with
6 higher neutralizing activity against pre-Omicron variants and that vaccination followed by
7 infection was associated with higher neutralizing activity against Omicron sub-lineages, in line
8 with the humoral response in other populations (health-care workers, healthy vaccinated adults
9 and adolescents as well as immunocompromised patients). Interestingly, we did not observe any
10 significant difference in the NtAb response in terms of sex, age, or male/female with chronic
11 diseases, smokers or vaping or among those volunteers with all three characteristics. Additional
12 public health measures may be warranted to increase antibody response against new SARS-CoV-
13 2 variants such as updated vaccines for the population.

14 15 **Supplementary Data**

16 Supplementary material associated with this article can be found in the online.

17 18 **Declaration of competing interest.**

19 The authors declared no competing interests.

20 21 **Funding**

22 This study was funded by the Public Health of Canada through the COVID-19 Immunity Task
23 Force (CITF) to CG, JP, JFM, DB, ST and MB. This research was supported in part by the Sentinel

1 North Research Chair at Université Laval (funded by the Canada First Research Excellence Fund)
2 and by the Canada Research Chair to M.B.

3

4 **Ethical approval**

5 This study was approved by the « Comité d'éthique de la recherche du CHU de Québec-Université
6 Laval (registration number 2021-5744). A unique, anonymized identifier was assigned to each
7 participant and used to store the data and the samples.

8

9 **Acknowledgements.** The authors sincerely acknowledge the nurses and research coordinators at
10 Centre de recherche du centre hospitalier universitaire de Québec for their involvement in this
11 study and all donors who agreed to participate in this research project. We are grateful to the
12 National Microbiology Laboratory (NML), Public Health Canada, for providing SARS-CoV-2
13 isolates (SARS-CoV-2 VOC B.1.617.2 (Delta), B1.1.529 (Omicron sub-lineage BA.1) and
14 Omicron sub-lineages BA.2, BA.2.12.1, BA.4 and BA.5 used in this study.

15

16 **Author contributions**

17 H.R. and M.B. designed the study. K.S. and S.T. wrote the clinical protocol and recruited the
18 participants. H.R., M.S., M.G. and M.B. performed the experiments. M.B. supervised the study.
19 H.R. and M.B. analyzed the data and wrote the manuscript. C.G., K.S., M.T., N.B., J.F.M., J.P.,
20 D.B., and S.T. revised the manuscript and provided scientific input. All authors have read and
21 approved the final manuscript.

22

23

24

References

1. Singh J, Rahman SA, Ehtesham NZ, Hira S, Hasnain SE. SARS-CoV-2 variants of concern are emerging in India. *Nat Med* **2021**; 27(7): 1131-3.
2. Liu C, Ginn HM, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. *Cell* **2021**; 184(16): 4220-36 e13.
3. Tian D, Sun Y, Zhou J, Ye Q. The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape. *Front Immunol* **2021**; 12: 751778.
4. Torjesen I. Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. *BMJ* **2021**; 375: n2943.
5. VanBlargan LA, Errico JM, Halfmann PJ, et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. *Nat Med* **2022**.
6. World Health Organization (WHO). Tracking SARS-CoV-2 variants. <https://www.who.int/activities/tracking-SARS-CoV-2-variants>. .
7. Kurhade C, Zou J, Xia H, et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster. *Nat Med* **2022**.
8. Addetia A, Crawford KHD, Dingens A, et al. Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. *J Clin Microbiol* **2020**; 58(11).
9. McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. *Nature* **2021**; 590(7847): 630-4.
10. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. *J Hyg (Lond)* **1972**; 70(4): 767-77.
11. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* **2021**; 27(7): 1205-11.
12. Science M, Bolotin S, Silverman M, et al. SARS-CoV-2 antibodies in Ontario health care workers during and after the first wave of the pandemic: a cohort study. *CMAJ Open* **2021**; 9(4): E929-E39.
13. Eldesoukey N, Gaafar T, Enein AA, et al. SARS-CoV-2 antibody seroprevalence rates among Egyptian blood donors around the third wave: Cross-sectional study. *Health Sci Rep* **2022**; 5(3): e634.
14. Lewin A, De Serres G, Gregoire Y, et al. Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study. *Can J Public Health* **2022**; 113(3): 385-93.
15. Zinszer K, McKinnon B, Bourque N, et al. Seroprevalence of SARS-CoV-2 Antibodies Among Children in School and Day Care in Montreal, Canada. *JAMA Netw Open* **2021**; 4(11): e2135975.
16. West EA, Kotoun OJ, Schori LJ, et al. Seroprevalence of SARS-CoV-2 antibodies, associated factors, experiences and attitudes of nursing home and home healthcare employees in Switzerland. *BMC Infect Dis* **2022**; 22(1): 259.

- 1 17. Kim Santerre, Mathieu Thériault, Nicholas Brousseau, Samuel Rochette, Joelle Pelletier,
2 Caroline Gilbert, Jean-Francois Masson, Mariana Baz, Denis Boudreau, Sylvie Trottier.
3 Cohort Profile: Prospective Cohort to Study the COVID-19 Immune Response in Retail
4 Workers in Quebec, Canada (CISACOV). medRxiv 2023.08.18.23294172; doi:
5 <https://doi.org/10.1101/2023.08.18.23294172>.
- 6 18. Baz M, Boonnak K, Paskel M, et al. Nonreplicating influenza A virus vaccines confer
7 broad protection against lethal challenge. MBio **2015**; 6(5): e01487-15.
- 8 19. Baz M, Paskel M, Matsuoka Y, et al. Replication and immunogenicity of swine, equine,
9 and avian h3 subtype influenza viruses in mice and ferrets. J Virol **2013**; 87(12): 6901-10.
- 10 20. Reed LJ, and H. Muench. . A simple method of estimating fifty percent endpoints. Am. J.
11 Hyg. 27:493–497. **1938**.
- 12 21. Qu P, Faraone J, Evans JP, et al. Neutralization of the SARS-CoV-2 Omicron BA.4/5 and
13 BA.2.12.1 Subvariants. N Engl J Med **2022**; 386(26): 2526-8.
- 14 22. Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants
15 BA.2.12.1, BA.4 and BA.5. Nature **2022**; 608(7923): 603-8.
- 16 23. Kurhade C, Zou J, Xia H, et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2,
17 BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med **2022**.
- 18 24. Wang Q, Bowen A, Valdez R, et al. Antibody Response to Omicron BA.4-BA.5 Bivalent
19 Booster. N Engl J Med **2023**.
- 20 25. Ionescu IG, Skowronski DM, Sauvageau C, et al. BNT162b2 effectiveness against Delta
21 and Omicron variants of SARS-CoV-2 in adolescents aged 12-17 years, by dosing interval
22 and duration. J Infect Dis **2023**.
- 23 26. Khoury DS, Schlub TE, Cromer D, et al. Correlates of Protection, Thresholds of
24 Protection, and Immunobridging among Persons with SARS-CoV-2 Infection. Emerg
25 Infect Dis **2023**; 29(2): 381-8.
- 26 27. Carazo S, Skowronski DM, Brisson M, et al. Protection against omicron (B.1.1.529) BA.2
27 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection
28 among health-care workers with and without mRNA vaccination: a test-negative case-
29 control study. Lancet Infect Dis **2023**; 23(1): 45-55.
- 30 28. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and
31 asymptomatic SARS-CoV-2 infection. Nat Med **2021**; 27(11): 2032-40.
- 32 29. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the
33 mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science **2022**; 375(6576): 43-50.
- 34 30. Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 Breakthrough Infections in Vaccinated
35 Health Care Workers. N Engl J Med **2021**; 385(16): 1474-84.
- 36 31. Wang B, Xu J, Wu S, et al. Comparative characterization of antibody responses induced
37 by Ad5-vectored spike proteins of emerging SARS-CoV-2 VOCs. Signal Transduct Target
38 Ther **2022**; 7(1): 257.
- 39 32. Banerjee A, Lew J, Kroeker A, et al. Immunogenicity of convalescent and vaccinated sera
40 against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants. Med
41 (N Y) **2022**; 3(6): 422-32 e3.
- 42 33. Mu X, Cohen CA, Leung D, et al. Antibody and T cell responses against wild-type and
43 Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents. Signal Transduct Target
44 Ther **2022**; 7(1): 397.

- 1 34. Cheng SMS, Mok CKP, Leung YWY, et al. Neutralizing antibodies against the SARS-CoV-2
2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2
3 vaccination. *Nat Med* **2022**; 28(3): 486-9.
- 4 35. Rosa Duque JS, Wang X, Leung D, et al. Immunogenicity and reactogenicity of SARS-CoV-
5 2 vaccines BNT162b2 and CoronaVac in healthy adolescents. *Nat Commun* **2022**; 13(1):
6 3700.
- 7 36. Ferreira VH, Solera JT, Hu Q, et al. Homotypic and heterotypic immune responses to
8 Omicron variant in immunocompromised patients in diverse clinical settings. *Nat*
9 *Commun* **2022**; 13(1): 4489.
- 10 37. Keppler-Hafkemeyer A, Greil C, Wratil PR, et al. Potent high-avidity neutralizing
11 antibodies and T cell responses after COVID-19 vaccination in individuals with B cell
12 lymphoma and multiple myeloma. *Nat Cancer* **2023**; 4(1): 81-95.
- 13 38. Nasr MC, Geerling E, Pinto AK. Impact of Obesity on Vaccination to SARS-CoV-2. *Front*
14 *Endocrinol (Lausanne)* **2022**; 13: 898810.
- 15 39. Fu C, Lin N, Zhu J, Ye Q. Association between Overweight/Obesity and the Safety and
16 Efficacy of COVID-19 Vaccination: A Systematic Review. *Vaccines (Basel)* **2023**; 11(5).
- 17 40. Hachmann NP, Miller J, Collier AY, et al. Neutralization Escape by SARS-CoV-2 Omicron
18 Subvariants BA.2.12.1, BA.4, and BA.5. *N Engl J Med* **2022**; 387(1): 86-8.

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

1 **Table 1: Demographic description and clinical characteristics of study participants.**
 2

	All participants	Female	Male
Participant, n (%)	280 (100)	158 (56)	122 (44)
Grocery store	105 (37)	52 (50)	53 (50)
Restaurant/bar	133 (48)	82 (62)	51 (38)
Hardware store	42 (15)	24 (57)	18 (43)
Age (years), median (range)	41 (18-74)	42 (18-70)	41 (18-74)
Grocery store	45 (18-74)	45 (18-70)	47 (18-74)
Restaurant/bar	35 (18-69)	38 (18-67)	32 (18-69)
Hardware store	53 (18-72)	51 (18-64)	58 (18-72)
Body Mass Index, median (range)	26 (17-50)	26 (17-50)	27 (18-47)
Grocery store	28 (17-39)	28 (17-39)	28 (18-37)
Restaurant/bar	25 (18-50)	24 (18-50)	26 (18-47)
Hardware store	25 (20-44)	26 (20-44)	25 (21-38)
Chronic disease, n (%)	117 (42)	67 (57)	50 (43)
Grocery store	51 (44)	25 (49)	26 (51)
Restaurant/bar	41 (35)	26 (63)	15 (37)
Hardware store	25 (21)	16 (64)	9 (36)
Smoking/Vaping, n (%)	59 (21)	32 (54)	27 (46)
Grocery store	17 (29)	9 (53)	8 (47)
Restaurant/bar	35 (63)	19 (51)	18 (49)
Hardware store	5 (8)	4 (80)	1 (20)

3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22

1 **Table 2: Median delay between last vaccine dose or infection and sample collection for**
 2 **groups 1 to 4.**
 3

Median delay between last vaccine dose or infection and sample collection (days)			
	1 dose Delay (n)	2 doses Delay (n)	3 doses Delay (n)
GROUP 1 (N=16)	315 (2)	168 (11)	13 (3)
Infected, vaccinated 1-3 doses			
Pfizer (1-3 doses)	336 (1)	126 (9)	13 (1)
Moderna (2-3 doses)	-	179 (2)	9 (1)
Mix Pfizer/Moderna	-	-	15 (1)
AstraZeneca (1 dose)	294 (1)	-	-
GROUP 2 (N=144)	-	157 (144)	-
Vaccinated 2 doses			
Pfizer (2 doses)	-	149 (85)	-
Moderna (2 doses)	-	156 (41)	-
Mix Pfizer/Moderna	-	98 (2)	-
AstraZeneca/Pfizer or Moderna	-	184 (16)	-
GROUP 3 (N=84)	-	-	48 (84)
Vaccinated 3 doses			
Pfizer (3 doses)	-	-	24 (17)
Moderna (3 doses)	-	-	60 (16)
Mix Pfizer/Moderna	-	-	39 (27)
Mix AstraZeneca/Pfizer or Moderna	-	-	49 (24)
GROUP 4 (N=36)	-	44 (28)	23 (8)
Vaccinated 2-3 doses, infected			
Pfizer (2-3 doses)	-	19 (18)	16 (5)
Moderna (2 doses)	-	50 (7)	-
Mix Pfizer/Moderna	-	-	54 (2)
AstraZeneca/Pfizer or Moderna	-	46 (3)	30 (1)

4
 5
 6
 7
 8
 9
 10
 11
 12

1 **Figure legends**

2

3 **Figure 1**

4 Comparison of live neutralizing antibody titers in participants after homologous or heterologous
5 vaccination, infection followed by vaccination or vice-versa. Food and retail workers received two
6 or three doses of mRNA vaccines (Pfizer, Moderna or AstraZeneca) or a combination of them. **(A)**
7 Serum neutralizing antibody of all participants against ancestral SARS-CoV-2, Delta, BA.1, BA.2,
8 BA.2.12.1, BA.4 and BA.5 strains. Each circle represents a single participant. Bars identify
9 geometric mean titers of the group. The horizontal dashed line indicates the limit of detection for
10 the neutralization assay (neutralizing titer of 10). The samples that did not neutralize SARS-CoV-
11 2 at 1:20 serum dilution was given a neutralizing titer of 10 for graphic representation and
12 statistical analysis. The fold-change of the geometric mean titer is denoted on the line. **(B)** Serum
13 neutralizing antibody of participants from grocery stores (105), restaurants/bar (133) and hardware
14 stores (42) against ancestral SARS-CoV-2, Delta, BA.1, BA.2, BA.2.12.1, BA.4 and BA.5 strains.
15 Significance was assessed with Kruskal-Wallis one-way ANOVA followed by Dunn's multiple
16 comparison test (* $p < 0.05$; **** $p < 0.0001$).

17

18 **Figure 2**

19 Neutralizing antibody titers in **(A)** males (n=122), **(B)** females (n=158), **(C)** <60 years (n=236,
20 median 37 (range 18-59) and **(D)** ≥60 years (n=44, median 64 (60-73) against ancestral SARS-
21 CoV-2, Delta, BA.1, BA.2, BA.2.12.1, BA.4 and BA.5 strains. Each circle represents a single
22 participant. Bars identify geometric mean titers of the group. The horizontal dashed line indicates
23 the limit of detection for the neutralization assay (neutralizing titer of 10). The samples that did
24 not neutralize SARS-CoV-2 at 1:20 serum dilution was given a neutralizing titer of 10 for graphic

1 representation and statistical analysis. The fold-change of the geometric mean titer is denoted on
2 the line. Significance was assessed with Kruskal-Wallis one-way ANOVA followed by Dunn's
3 multiple comparison test (* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$).

4

5 **Figure 3**

6 Neutralizing antibody titers against ancestral SARS-CoV-2, Delta, BA.1, BA.2, BA.2.12.1, BA.4
7 and BA.5 strains in all volunteers regarding the number of vaccine doses received and if they were
8 infected before or after vaccinations. **(A)** Group 1 (n=16); infected, Pfizer (n=11), Moderna (n=3),
9 Pfizer/Moderna (n=1) or AstraZeneca (n=1)); Groupe 2 (n=144); 2 doses of Pfizer (n=85),
10 Pfizer/Moderna or vice versa (n=2), Moderna/Moderna (n=41) and AstraZeneca and Pfizer or
11 Moderna (n=16); Group 3 (n=84); 3 doses of Pfizer (n=17), 3 doses of Moderna (n=16),
12 Moderna/Moderna/Pfizer (n=5), Pfizer/Pfizer/Moderna (n=19), Pfizer/Moderna/Pfizer or
13 Moderna (n=3), AstraZeneca/AstraZeneca/Pfizer or Moderna (n=4) or AstraZeneca/Pfizer or
14 Moderna/Moderna (n=20); Group 4 (n=36): participants received at least 2 doses of vaccine
15 (Pfizer/Pfizer (n=25), Moderna/Moderna (n=7), AstraZeneca/ AstraZeneca or
16 AstraZeneca/Moderna (n=4)) and then were infected. **(B)** Neutralizing antibody titers for each
17 participant against ancestral SARS-CoV-2, Delta, BA.1, BA.2, BA.2.12.1, BA.4 and BA.5 strains
18 regarding type of vaccine regimen. Each circle represents a single participant. In the first group,
19 the green and red points represent participants vaccinated with 1 and 3 doses and then infected,
20 respectively. Bars identify geometric mean titers of the group. The horizontal dashed line indicates
21 the limit of detection for the neutralization assay (neutralizing titer of 10). The samples that did
22 not neutralize SARS-CoV-2 at 1:20 serum dilution was given a neutralizing titer of 10 for graphic
23 representation and statistical analysis. The fold-change of the geometric mean titer is denoted on

1 the line. Significance was assessed with Kruskal-Wallis one-way ANOVA followed by Dunn's
2 multiple comparison test ($*p < 0.05$; $**p < 0.01$; $***p < 0.001$; $****p < 0.0001$).

3

4 **Supplementary Figure 1**

5 Neutralizing antibody titers after the most recent vaccine dose or infection and the sample
6 collection. Time was grouped into 7-30 days, 31-60 days, 61-90 days and over 90 days. **(A)** Groupe
7 1, infected, then vaccinated with ≥ 1 dose. **(B)** Groupe 2, vaccinated with 2 doses **(C)** Groupe 3,
8 vaccinated with 3 doses. **(D)** Groupe 4, vaccinated with ≥ 2 dose and infected. Significance was
9 assessed with Kruskal-Wallis one-way ANOVA followed by Dunn's multiple comparison test
10 ($**p < 0.01$; $***p < 0.001$).

11

12 **Supplementary Figure 2**

13 Neutralizing antibody titers against ancestral SARS-CoV-2, Delta, BA.1, BA.2, BA.2.12.1, BA.4
14 and BA.5 strains for each of the groups: (grocery stores (n=105), hardware stores (n=42) and
15 restaurant/bars (n=133)). Each circle represents a single participant. Bars identify geometric mean
16 titers of the group. The horizontal dashed line indicates the limit of detection for the neutralization
17 assay (neutralizing titer of 10). The samples that did not neutralize SARS-CoV-2 at 1:20 serum
18 dilution was given a neutralizing titer of 10 for graphic representation and statistical analysis. The
19 fold-change of the geometric mean titer is denoted on the line. Significance was assessed with
20 Kruskal-Wallis one-way ANOVA followed by Dunn's multiple comparison test ($*p < 0.05$; $**p$
21 < 0.01 ; $***p < 0.001$; $****p < 0.0001$).

22

23

1 **Supplementary Figure 3**

2 Neutralizing antibody titers against ancestral SARS-CoV-2, Delta, BA.1, BA.2, BA.2.12.1, BA.4
3 and BA.5 strains in male and female with BMI ≥ 30 , chronic disease, smokers or vaping or among
4 those volunteers with all three characteristics. Each circle represents a single participant. Bars
5 identify geometric mean titers of the group. The horizontal dashed line indicates the limit of
6 detection for the neutralization assay (neutralizing titer of 10). The samples that did not neutralize
7 SARS-CoV-2 at 1:20 serum dilution were given a neutralizing titer of 10 for graphic representation
8 and statistical analysis. Significance was assessed with Kruskal-Wallis one-way ANOVA
9 followed by Dunn's multiple comparison test (* $p < 0.05$; ** $p < 0.01$).

10

11

12

All participants (n=280)





Figure 1A

Serum neutralizing antibody titers



G = Grocery (n=105)

R/B = Restaurant / Bar (n=133)

H = Hardware (n=42)

Figure 1B

A Male (n=122)

B Female (n=158)





Figure 2

C <60 years (n=236)

D ≥60 years (n=44)






Figure 2

Serum neutralizing antibody titers




- 1 = Infected, vaccinated 1-3 doses (n=16)
- 2 = Vaccinated 2 doses (n=144)
- 3 = Vaccinated 3 doses (n=84)
- 4 = Vaccinated 2-3 doses, infected (n=36)


Figure 3A

- Infected, vaccinated 1-3 doses
- Vaccinated 2 doses
- Vaccinated 3 doses
- Vaccinated 2-3 doses, infected


Ancestral




Delta




BA.1




BA.2



BA.2.12.1



BA.4



BA.5




Figure 3B